BiotechTube
OM Pharma

OM Pharma

Geneva, Switzerland· Est.
ompharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

OM Pharma is a long-established Swiss biopharmaceutical company with a specialized focus on bacterial immunotherapies for infection prevention and vascular diseases. Its core business model revolves around developing and commercializing immunomodulatory products, primarily derived from bacterial lysates, to train the immune system. The company has a global commercial footprint with a portfolio of approved products, positioning it in the 'Commercial' stage. As a private company, it leverages decades of experience in microbial-based therapeutics.

Infectious DiseaseImmunologyVascular Diseases

Technology Platform

Bacterial immunomodulation platform specializing in polyvalent bacterial lysates and microbial-derived formulations to train and modulate the immune system for infection prevention and treatment.

Opportunities

The global push for antimicrobial stewardship creates a significant tailwind for non-antibiotic preventive therapies like OM Pharma's bacterial lysates.
Expanding into new geographic markets and generating robust real-world evidence can drive further adoption.
The platform also holds potential for exploration in adjacent areas like microbiome modulation.

Risk Factors

Regulatory pathways for bacterial immunotherapies are complex and vary by region, posing challenges for market expansion.
The clinical mechanism of polyvalent lysates can face skepticism, requiring continuous high-level evidence generation.
The company is also exposed to competitive, geopolitical, and currency risks from its focus on ex-US markets.

Competitive Landscape

OM Pharma competes in niche segments: for infection prevention, it faces competition from other bacterial lysate products, some vaccines, and general immune support products. In vascular diseases, it competes with a range of vasoactive drugs, generics, and interventional procedures. Its primary competitive advantage is its long-established brand, extensive clinical data, and specialized focus on bacterial immunomodulation.

More companies in Switzerland →